The formerly NZX-listed medicinal cannabis firm was placed into receivership by its noteholders in May.
Shareholders accepted deal with Danish company would go ahead "despite an angry minority."
The operations could sell for as much as $A500 million.
The competition is stacking up with at least three other medicinal cannabis companies already on the scene.
Can this spur the change NZX needs to survive?
Judge orders company must stay on register as liquidators investigate.
Warren Buffett buys into fintech companies in Brazil and India.
Controlling shareholder walks away as SEC probe nears conclusion.
Watch Grant Walker's video of today's top stories.
But why then did its share price rise?